Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2007 Oct;92(10):842-6.
doi: 10.1136/adc.2006.107581. Epub 2007 Apr 20.

Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening

Marco Cipolli  1 , Carlo Castellani, Bridget Wilcken, John Massie, Karen McKay, Margie Gruca, Anna Tamanini, Maurice Baroukh Assael, Kevin Gaskin
Affiliations
Multicenter Study

Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening

Marco Cipolli et al. Arch Dis Child. 2007 Oct.

Abstract

Objective: To determine the pancreatic phenotype of infants with cystic fibrosis (CF) diagnosed in the first week of life by a combined immunoreactive trypsin/mutation screening program.

Design: A prospective evaluation of pancreatic function in infants with CF at the time of neonatal diagnosis and up to the age of 12.

Setting: Two different centres (Verona, Italy and Westmead, Australia) to enable comparison of results between two regions where <60% or > or =90% of patients, respectively, have at least one single DeltaF508 a mutation.

Patients: 315 children with CF including 149 at Verona and 166 at Westmead.

Interventions: Fat balance studies over 3-5 days and pancreatic stimulation tests with main outcome measures being faecal fat or pancreatic colipase secretion. PATIENTS with malabsorption are pancreatic insufficient (PI) or with normal absorption and pancreatic sufficient (PS).

Results: 34 infants (23%) at Verona and 46 (28%) at Westmead were PS at diagnosis. 15% of those with two class I, II or III "severe" mutations and 26/28 (93%) of those with class IV or V mutations were PS at this early age. Of the 80 infants with PS, 20 became PI before the age of 12. All 20 had two severe mutations.

Conclusion: Neonatal mutational screening programs for CF are less likely to detect PS patients with non-DeltaF508 mutations. Of PS patients who are detected, those with two severe class I, II or III mutations are at particularly high risk of becoming PI during early childhood.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None of the authors have any affiliations, financial agreements or other involvement with any of the companies whose products are mentioned in this manuscript.

Comment in

References

    1. Crossley J R, Smith P A, Gluckman P D.et al Neonatal screening for cystic fibrosis, using immunoreactive trypsin assay in dried blood spots. Clin Chim Acta 1981113111–121. - PubMed
    1. Wilcken B, Brown A R, Urwin R.et al Cystic fibrosis screening by dried blood spot trypsin assay: results in 75,000 newborn infants. J Pediatr 1983102383–387. - PubMed
    1. Ad Hoc Committee Task Force on Neonatal Screening, Cystic Fibrosis Foundation Neonatal screening for cystic fibrosis: position paper. Pediatrics 198372741–745. - PubMed
    1. Waters D L, Dorney S F A, Gaskin K J.et al Pancreatic function in infants identified as having cystic fibrosis in a neonatal program. N Engl J Med 1990332303–308. - PubMed
    1. Gaskin K, Waters D, Dorney S.et al Assessment of pancreatic function in screened infants with cystic fibrosis. Pediatr Pulmonol Suppl 1991769–71. - PubMed